Objective:To evaluate the therapeutic effect of endostar(ED) combined with cisplatin(DDP) on model of C57BL/6 rats,and to further investigate the inhibiting mechanism of endostar from tumor angiogenesis.Methods:Lewis ...Objective:To evaluate the therapeutic effect of endostar(ED) combined with cisplatin(DDP) on model of C57BL/6 rats,and to further investigate the inhibiting mechanism of endostar from tumor angiogenesis.Methods:Lewis lung cancer cells were inoculated in C57BL/6 mouse,then the mouse were randomized into control group(group A),ED(group B),DDP(group C) and ED/DDP (group D).They were treated according to the plan.And the expressions of VEGF and Sema3A were evaluated by immunhistochemisty.Results:The weight of tumor increased in group A and B.It was decreased in group C and D.The tumor volume was increased in all the 4 groups. The VEGF expression of group D was obviously lower than the other group 3,but the Sema3A expressed of group D was significantly strengthener than the other group 3.The VEGF expression of group B and group D were obviously low especially in the 4th-8th days.Pearson correlated analysis showed that the expression VEGF and Sema3A were negatively correlated(r=-0.72, P【0.05).Conclusions:ED combined with DDP could control the tumor growth effectively,and avoid weight loss.ED could reduce VEGF expression,and enhance Sema3A expression.Tumor vessel presents transient normalization.It is easy for DDP perfusion,and to kill tumor cells.展开更多
The inhibitory effects of Endostar in combination with radiotherapy in BALB/c nude mice model of human CNE2 nasopharyngeal carcinoma and the mechanism were investigated.In nude mice model of CNE2 nasopharyngeal carcin...The inhibitory effects of Endostar in combination with radiotherapy in BALB/c nude mice model of human CNE2 nasopharyngeal carcinoma and the mechanism were investigated.In nude mice model of CNE2 nasopharyngeal carcinoma,the inhibitory rate and the sensitizing enhancement ratio(E/O) were calculated according to the tumor volumes in different groups.The expression of microvascular density(MVD) in tumor tissues was examined by using immunohistochemistry staining.The transcription of VEGF gene was detected by using RT-PCR.The inhibitory rate in Endostar+radiotherapy group was higher than in other groups.In Endostar+radiotherapy group,the tumor volume was significantly decreased and the E/O ratio was 2.335,suggesting that Endostar could be a radiosensitizer.The expression of MVD of tumor tissues in Endostar+radiotherapy group was reduced significantly.The expression of the MVD in treatment groups was significantly different from that in control group(P〈0.05).Compared to other groups,VEGF mRNA expression in Endostar+radiotherapy group was decreased remarkably.Endostar in combination with radiotherapy significantly inhibited the growth of CNE2 tumor.The combination therapy decreased the expression of VEGF,and inhibited tumor angiogenesis and proliferation.When combined with radiotherapy,Endostar acted as a radiosensitizer.展开更多
Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth fa...Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor(EGFR)-/anaplastic lymphoma kinase(ALK)-lung adenocarcinoma. Methods Sixty-four pCVatients with EGFR-/ALK-lung adenocarcinoma with malignant pleural effusion(MPE) were admitted to the authors' hospital between January 2016 and June 2017. Patients were randomly divided into two groups: Endostar combined with pemetrexed/cisplatin(Endostar group); and bevacizumab plus pemetrexed/cisplatin(Bevacizumab group). They underwent thoracic puncture and catheterization, and MPE was drained as much as possible. Both groups were treated with pemetrexed 500 mg/m^2, intravenous drip(d1), cisplatin 37.5 mg/m^2 per time, intra-pleural injection(d1, d3). Patients in the Endostar group were treated with Endostar 30 mg per time, intra-pleural injection(d1, 3), and patients in the Bevacizumab group were treated with bevacizumab 5 mg/kg per time, intra-pleural injection(d1). Only one cycle of treatment was applied. MPE was extracted before treatment and on day 7 after treatment. The levels of vascular endothelial growth factor(VEGF) were determined using ELISA. Efficacy and side effects were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1, and National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) version 3.0 criteria. Results The objective response rates in the Endostar and Bevacizumab groups were 50.0% and 56.3%, respectively; there was no statistical difference between the groups(P > 0.05). After one cycle of treatment, the mean VEGF levels in MPE in both groups decreased significantly, and there was no significant difference in the degree of decline between the two groups(P > 0.05). In both groups, pre-treatment VEGF levels for patients achieving complete response were significantly higher than those for patients achieving stable disease + progressive disease(P < 0.05). No specific side effects were recorded. Conclusion Endostar and Bevacizumab demonstrated similar efficacy in controlling MPE in patients with EGFR-/ALK-lung adenocarcinoma through an anti-angiogenesis pathway, with tolerable side effects. The levels of VEGF in MPE could predict the efficacy of intra-pleural injection of anti-angiogenesis drugs.展开更多
Objective: To explore the effect of endostar combined with taxol on tumor markers, vascular endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell proliferation and migration in NSCLC pat...Objective: To explore the effect of endostar combined with taxol on tumor markers, vascular endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell proliferation and migration in NSCLC patients. Methods Patients with advanced NSCLC were studied. The patients in the control group received chemotherapy with paclitaxel combined with cisplatin. Patients in the combination group received intravenous infusion of endostar on the basis of treatment of patients in the control group. 21 days was a cycle, and all patients were treated for 2 cycles. Fasting venous blood 3mL of all patients before and after treatment was collected, and CEA and saccharide antigen (CA50) were detected by radioimmunoassay. Vascular endothelial growth factor (VEGF), neuron-specific enolase (NSE), serum matrix metalloproteinase (MMP-2, MMP-9), high-mobility family protein at-hook 2 (HMGA 2) and high-mobility family protein B 1 (HMGB 1) were detected by ELISA. Results There were no significant differences in serum CA50, CEA, VEGF, NSE, mmp-2, mmp-9, HMGB 1, and HMGA 2 between the two groups before treatment (P>0.05). After two courses of chemotherapy, CA50, CEA, VEGF, NSE, MMP-2, MMP-9, HMGB 1, and HMGA 2 in the combination group and control group were significantly lower than before treatment (P<0.05), and the combination group was significantly lower than the control group (P<0.05). Conclusion Endostar combined with paclitaxel can enhance the chemotherapy effect of NSCLC patients, reduce the level of serum tumor markers, neuronal specific enolase and vascular endothelial growth factor, and inhibit the proliferation and migration of tumor cells.展开更多
Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(m RCC) and pleural effusion. Methods A total o...Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(m RCC) and pleural effusion. Methods A total of 10 patients with m RCC(8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib(400 mg, twice daily), while six received sunitinib(50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar(15 mg on days 1–4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild.Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with m RCC with pleural effusion, and may control local symptoms.展开更多
Objective:To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma.Methods:From August 2016 to September 2020,32 patients with lung a...Objective:To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma.Methods:From August 2016 to September 2020,32 patients with lung adenocarcinoma who were treated in our hospital were selected for group trials.According to their specific treatment plan,the patients were divided into control group and experimental group,with 16 cases in each group.The control group was treated with pemetrexed and cisplatin,and the experimental group was treated with Endostar combined with the treatment received by the control group.The clinical efficacy and safety of the two regimens were assessed by comparing the changes in symptoms and the incidence of adverse reactions between the two groups of patients after treatment.Results:The disease control rate of the experimental group was significantly higher than that of the control group,and there was no significant difference in the incidence of adverse reactions between the two groups.Conclusions:From the experimental results,we found that the treatment of patients with lung adenocarcinoma by Endostar combined with pemetrexed and cisplatin can effectively improve the treatment efficacy without increasing adverse reactions and therefore relevant chemotherapy regimens can be considered for wider clinical applications.展开更多
文摘Objective:To evaluate the therapeutic effect of endostar(ED) combined with cisplatin(DDP) on model of C57BL/6 rats,and to further investigate the inhibiting mechanism of endostar from tumor angiogenesis.Methods:Lewis lung cancer cells were inoculated in C57BL/6 mouse,then the mouse were randomized into control group(group A),ED(group B),DDP(group C) and ED/DDP (group D).They were treated according to the plan.And the expressions of VEGF and Sema3A were evaluated by immunhistochemisty.Results:The weight of tumor increased in group A and B.It was decreased in group C and D.The tumor volume was increased in all the 4 groups. The VEGF expression of group D was obviously lower than the other group 3,but the Sema3A expressed of group D was significantly strengthener than the other group 3.The VEGF expression of group B and group D were obviously low especially in the 4th-8th days.Pearson correlated analysis showed that the expression VEGF and Sema3A were negatively correlated(r=-0.72, P【0.05).Conclusions:ED combined with DDP could control the tumor growth effectively,and avoid weight loss.ED could reduce VEGF expression,and enhance Sema3A expression.Tumor vessel presents transient normalization.It is easy for DDP perfusion,and to kill tumor cells.
基金supported by a grant from the National Natural Sciences Foundation of China (No. 30470525)
文摘The inhibitory effects of Endostar in combination with radiotherapy in BALB/c nude mice model of human CNE2 nasopharyngeal carcinoma and the mechanism were investigated.In nude mice model of CNE2 nasopharyngeal carcinoma,the inhibitory rate and the sensitizing enhancement ratio(E/O) were calculated according to the tumor volumes in different groups.The expression of microvascular density(MVD) in tumor tissues was examined by using immunohistochemistry staining.The transcription of VEGF gene was detected by using RT-PCR.The inhibitory rate in Endostar+radiotherapy group was higher than in other groups.In Endostar+radiotherapy group,the tumor volume was significantly decreased and the E/O ratio was 2.335,suggesting that Endostar could be a radiosensitizer.The expression of MVD of tumor tissues in Endostar+radiotherapy group was reduced significantly.The expression of the MVD in treatment groups was significantly different from that in control group(P〈0.05).Compared to other groups,VEGF mRNA expression in Endostar+radiotherapy group was decreased remarkably.Endostar in combination with radiotherapy significantly inhibited the growth of CNE2 tumor.The combination therapy decreased the expression of VEGF,and inhibited tumor angiogenesis and proliferation.When combined with radiotherapy,Endostar acted as a radiosensitizer.
基金Supported by a grant from the Nature Science Foundation of Hubei Province,China(No.2017CFB472)
文摘Objective To compare intra-pleural injection efficacy and safety between Endostar and bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor(EGFR)-/anaplastic lymphoma kinase(ALK)-lung adenocarcinoma. Methods Sixty-four pCVatients with EGFR-/ALK-lung adenocarcinoma with malignant pleural effusion(MPE) were admitted to the authors' hospital between January 2016 and June 2017. Patients were randomly divided into two groups: Endostar combined with pemetrexed/cisplatin(Endostar group); and bevacizumab plus pemetrexed/cisplatin(Bevacizumab group). They underwent thoracic puncture and catheterization, and MPE was drained as much as possible. Both groups were treated with pemetrexed 500 mg/m^2, intravenous drip(d1), cisplatin 37.5 mg/m^2 per time, intra-pleural injection(d1, d3). Patients in the Endostar group were treated with Endostar 30 mg per time, intra-pleural injection(d1, 3), and patients in the Bevacizumab group were treated with bevacizumab 5 mg/kg per time, intra-pleural injection(d1). Only one cycle of treatment was applied. MPE was extracted before treatment and on day 7 after treatment. The levels of vascular endothelial growth factor(VEGF) were determined using ELISA. Efficacy and side effects were evaluated according to the Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1, and National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) version 3.0 criteria. Results The objective response rates in the Endostar and Bevacizumab groups were 50.0% and 56.3%, respectively; there was no statistical difference between the groups(P > 0.05). After one cycle of treatment, the mean VEGF levels in MPE in both groups decreased significantly, and there was no significant difference in the degree of decline between the two groups(P > 0.05). In both groups, pre-treatment VEGF levels for patients achieving complete response were significantly higher than those for patients achieving stable disease + progressive disease(P < 0.05). No specific side effects were recorded. Conclusion Endostar and Bevacizumab demonstrated similar efficacy in controlling MPE in patients with EGFR-/ALK-lung adenocarcinoma through an anti-angiogenesis pathway, with tolerable side effects. The levels of VEGF in MPE could predict the efficacy of intra-pleural injection of anti-angiogenesis drugs.
基金Science and Technology Project of Jiangsu Provincial Hospital of Traditional Chinese Medicine (Y14066)
文摘Objective: To explore the effect of endostar combined with taxol on tumor markers, vascular endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell proliferation and migration in NSCLC patients. Methods Patients with advanced NSCLC were studied. The patients in the control group received chemotherapy with paclitaxel combined with cisplatin. Patients in the combination group received intravenous infusion of endostar on the basis of treatment of patients in the control group. 21 days was a cycle, and all patients were treated for 2 cycles. Fasting venous blood 3mL of all patients before and after treatment was collected, and CEA and saccharide antigen (CA50) were detected by radioimmunoassay. Vascular endothelial growth factor (VEGF), neuron-specific enolase (NSE), serum matrix metalloproteinase (MMP-2, MMP-9), high-mobility family protein at-hook 2 (HMGA 2) and high-mobility family protein B 1 (HMGB 1) were detected by ELISA. Results There were no significant differences in serum CA50, CEA, VEGF, NSE, mmp-2, mmp-9, HMGB 1, and HMGA 2 between the two groups before treatment (P>0.05). After two courses of chemotherapy, CA50, CEA, VEGF, NSE, MMP-2, MMP-9, HMGB 1, and HMGA 2 in the combination group and control group were significantly lower than before treatment (P<0.05), and the combination group was significantly lower than the control group (P<0.05). Conclusion Endostar combined with paclitaxel can enhance the chemotherapy effect of NSCLC patients, reduce the level of serum tumor markers, neuronal specific enolase and vascular endothelial growth factor, and inhibit the proliferation and migration of tumor cells.
文摘Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(m RCC) and pleural effusion. Methods A total of 10 patients with m RCC(8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib(400 mg, twice daily), while six received sunitinib(50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar(15 mg on days 1–4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild.Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with m RCC with pleural effusion, and may control local symptoms.
文摘Objective:To analyze and study the efficacy and safety of Endu combined with pemetrexed and cisplatin in the clinical treatment of lung adenocarcinoma.Methods:From August 2016 to September 2020,32 patients with lung adenocarcinoma who were treated in our hospital were selected for group trials.According to their specific treatment plan,the patients were divided into control group and experimental group,with 16 cases in each group.The control group was treated with pemetrexed and cisplatin,and the experimental group was treated with Endostar combined with the treatment received by the control group.The clinical efficacy and safety of the two regimens were assessed by comparing the changes in symptoms and the incidence of adverse reactions between the two groups of patients after treatment.Results:The disease control rate of the experimental group was significantly higher than that of the control group,and there was no significant difference in the incidence of adverse reactions between the two groups.Conclusions:From the experimental results,we found that the treatment of patients with lung adenocarcinoma by Endostar combined with pemetrexed and cisplatin can effectively improve the treatment efficacy without increasing adverse reactions and therefore relevant chemotherapy regimens can be considered for wider clinical applications.